Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Life Sci Alliance ; 6(9)2023 09.
Article in English | MEDLINE | ID: mdl-37348953

ABSTRACT

The CTP nucleotide is a key precursor of nucleic acids metabolism essential for DNA replication. De novo CTP production relies on CTP synthetases 1 and 2 (CTPS1 and CTPS2) that catalyze the conversion of UTP into CTP. CTP synthetase activity is high in proliferating cells including cancer cells; however, the respective roles of CTPS1 and CTPS2 in cell proliferation are not known. By inactivation of CTPS1 and/or CTPS2 and complementation experiments, we showed that both CTPS1 and CTPS2 are differentially required for cell proliferation. CTPS1 was more efficient in promoting proliferation than CTPS2, in association with a higher intrinsic enzymatic activity that was more resistant to inhibition by 3-deaza-uridine, an UTP analog. The contribution of CTPS2 to cell proliferation was modest when CTPS1 was expressed but essential in absence of CTPS1. Public databases analysis of more than 1,000 inactivated cancer cell lines for CTPS1 or CTPS2 confirmed that cell growth is highly dependent of CTPS1 but less or not of CTPS2. Therefore, our results demonstrate that CTPS1 is the main contributor to cell proliferation.


Subject(s)
Carbon-Nitrogen Ligases , Carbon-Nitrogen Ligases/genetics , Carbon-Nitrogen Ligases/metabolism , Uridine Triphosphate/metabolism , Cell Proliferation , Cell Cycle , Cell Line
2.
Hemasphere ; 7(4): e864, 2023 Apr.
Article in English | MEDLINE | ID: mdl-37008165

ABSTRACT

Lymphoma is the most common hematological malignancy and is among the 10 most prevalent cancers worldwide. Although survival has been improved by modern immunochemotherapeutic regimens, there remains a significant need for novel targeted agents to treat both B-cell and T-cell malignancies. Cytidine triphosphate synthase 1 (CTPS1), which catalyzes the rate-limiting step in pyrimidine synthesis, plays an essential and nonredundant role in B-cell and T-cell proliferation but is complemented by the homologous CTPS2 isoform outside the hemopoietic system. This report describes the identification and characterization of CTPS1 as a novel target in B- and T-cell cancers. A series of small molecules have been developed which show potent and highly selective inhibition of CTPS1. Site-directed mutagenesis studies identified the adenosine triphosphate pocket of CTPS1 as the binding site for this small molecule series. In preclinical studies, a potent and highly selective small molecule inhibitor of CTPS1 blocked the in vitro proliferation of human neoplastic cells, showing the highest potency against lymphoid neoplasms. Importantly, pharmacological CTPS1 inhibition induced cell death by apoptosis in the majority of lymphoid cell lines tested, thus demonstrating a cytotoxic mechanism of action. Selective CTPS1 inhibition also inhibited the growth of neoplastic human B- and T- cells in vivo. These findings identify CTPS1 as a novel therapeutic target in lymphoid malignancy. A compound from this series is in phase 1/2 clinical studies for the treatment of relapsed/refractory B- and T-cell lymphoma (NCT05463263).

3.
J Med Chem ; 65(24): 16640-16650, 2022 12 22.
Article in English | MEDLINE | ID: mdl-36449304

ABSTRACT

Herein, we report the discovery of a first-in-class chemotype 2-(alkylsulfonamido)thiazol-4-yl)acetamides that act as pan-selective inhibitors of cytidine 5'-triphosphate synthetase (CTPS1/2), critical enzymes in the de novo pyrimidine synthesis pathway. Weak inhibitors identified from a high-throughput screening of 240K compounds have been optimized to a potent, orally active agent, compound 27, which has shown significant pharmacological responses at 10 mg/kg dose BID in a well-established animal model of inflammation.


Subject(s)
Carbon-Nitrogen Ligases , Enzyme Inhibitors , Animals , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use , Carbon-Nitrogen Ligases/metabolism , Cell Proliferation , High-Throughput Screening Assays
4.
J Biol Chem ; 288(51): 36636-47, 2013 Dec 20.
Article in English | MEDLINE | ID: mdl-24194519

ABSTRACT

The neutrophil enzyme myeloperoxidase (MPO) promotes oxidative stress in numerous inflammatory pathologies by producing hypohalous acids. Its inadvertent activity is a prime target for pharmacological control. Previously, salicylhydroxamic acid was reported to be a weak reversible inhibitor of MPO. We aimed to identify related hydroxamates that are good inhibitors of the enzyme. We report on three hydroxamates as the first potent reversible inhibitors of MPO. The chlorination activity of purified MPO was inhibited by 50% by a 5 nm concentration of a trifluoromethyl-substituted aromatic hydroxamate, HX1. The hydroxamates were specific for MPO in neutrophils and more potent toward MPO compared with a broad range of redox enzymes and alternative targets. Surface plasmon resonance measurements showed that the strength of binding of hydroxamates to MPO correlated with the degree of enzyme inhibition. The crystal structure of MPO-HX1 revealed that the inhibitor was bound within the active site cavity above the heme and blocked the substrate channel. HX1 was a mixed-type inhibitor of the halogenation activity of MPO with respect to both hydrogen peroxide and halide. Spectral analyses demonstrated that hydroxamates can act variably as substrates for MPO and convert the enzyme to a nitrosyl ferrous intermediate. This property was unrelated to their ability to inhibit MPO. We propose that aromatic hydroxamates bind tightly to the active site of MPO and prevent it from producing hypohalous acids. This mode of reversible inhibition has potential for blocking the activity of MPO and limiting oxidative stress during inflammation.


Subject(s)
Enzyme Inhibitors/pharmacology , Hydrocarbons, Aromatic/pharmacology , Hydroxamic Acids/pharmacology , Peroxidase/chemistry , Amino Acid Sequence , Binding Sites , Cell Line, Tumor , Enzyme Inhibitors/chemistry , Humans , Hydrocarbons, Aromatic/chemical synthesis , Hydrocarbons, Aromatic/chemistry , Hydroxamic Acids/chemistry , Kinetics , Molecular Docking Simulation , Molecular Sequence Data , Neutrophils/enzymology , Peroxidase/antagonists & inhibitors , Peroxidase/metabolism , Protein Binding
5.
Bioorg Med Chem Lett ; 21(1): 531-6, 2011 Jan 01.
Article in English | MEDLINE | ID: mdl-21075629

ABSTRACT

We describe the discovery of small molecule benzazepine derivatives as agonists of human peroxisome proliferator-activated receptor δ (PPARδ) that displayed excellent selectivity over the PPARα and PPARγ subtypes. Compound 8 displayed good PK in the rat and efficacy in upregulation of pyruvate dehydrogenase kinase, isozyme 4 (PDK4) mRNA in human primary myotubes, a biomarker for increased fatty acid oxidation.


Subject(s)
Anilides/chemical synthesis , Benzazepines/chemistry , PPAR delta/agonists , Anilides/chemistry , Anilides/pharmacokinetics , Animals , Benzazepines/chemical synthesis , Benzazepines/pharmacokinetics , Binding Sites , Computer Simulation , Hepatocytes/metabolism , Humans , Microsomes, Liver/metabolism , PPAR alpha/agonists , PPAR alpha/metabolism , PPAR delta/metabolism , PPAR gamma/agonists , PPAR gamma/metabolism , Protein Serine-Threonine Kinases/genetics , Protein Serine-Threonine Kinases/metabolism , Pyruvate Dehydrogenase Acetyl-Transferring Kinase , Rats , Up-Regulation
6.
Bioorg Med Chem Lett ; 19(4): 1143-7, 2009 Feb 15.
Article in English | MEDLINE | ID: mdl-19171482

ABSTRACT

A novel series of small molecule C5a antagonists is reported. In particular, in vitro metabolic studies and solution based combinatorial synthesis are demonstrated as useful tools for the rapid identification of antagonists with low in vitro clearance. Members of this series specifically inhibited the binding of (125)I-labeled C5a to human recombinant C5a receptor (C5aR). In functional cell assays these compounds displayed surmountable antagonism against C5a and did not demonstrate any detectable agonist activity.


Subject(s)
Amides/chemical synthesis , Amides/pharmacology , Benzene Derivatives/chemical synthesis , Benzene Derivatives/pharmacology , Furans/chemical synthesis , Furans/pharmacology , Receptors, Complement/antagonists & inhibitors , Amides/chemistry , Animals , Benzene Derivatives/chemistry , Combinatorial Chemistry Techniques , Dogs , Furans/chemistry , Humans , Mice , Microsomes, Liver/metabolism , Molecular Structure , Rats , Rats, Sprague-Dawley , Receptor, Anaphylatoxin C5a , Stereoisomerism , Structure-Activity Relationship
7.
Mol Immunol ; 43(9): 1432-42, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16213022

ABSTRACT

The polymerase chain reaction was used to screen human peripheral blood mononuclear cells (PBMC) and Jurkat cells for the presence of GABAA receptor subunit mRNAs. Positive signals were detected for the alpha1, alpha3, beta2, beta3, delta and epsilon subunit mRNAs in both cell populations, with the Jurkat cells giving a positive signal for some additional species. Real-time PCR was used to confirm that PBMC, lymphocytes and monocytes contained significant levels of the alpha1 subunit mRNA and that PBMC and lymphocytes contained low levels of beta2 mRNA. The alpha1 subunit was detected in PBMC and fractionated T-cell populations, as well as Jurkat and HL-60 cell lines, by Western blotting and immunofluorescence using a specific antibody. The application of 1mM GABA reduced the specific increase in intracellular PBMC Ca2+ levels produced by addition of 1 nM fMLP: this effect was mimicked by muscimol, but not glycine, and was blocked by bicuculline. The inhibitory effect of GABA was limited to a subset of PBMC. We conclude that cells within the human PBMC population, including lymphocytes, express functional GABAA receptors and these receptors may modulate immune responses.


Subject(s)
Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Receptors, GABA-A/chemistry , Receptors, GABA-A/genetics , Animals , Base Sequence , Cell Line , DNA, Complementary/genetics , Gene Expression , HL-60 Cells , Humans , In Vitro Techniques , Jurkat Cells , Mice , Protein Subunits , RNA, Messenger/genetics , RNA, Messenger/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...